AstraZeneca’s England approval of Enhertu signals wider access to cancer care, expanding NHS treatment options for eligible breast cancer patients.
Science still finds insufficient evidence to support stem cell therapy as standard care for autism, keeping the treatment within clinical trials.
Today’s pharma deals map the full innovation cycle, spanning oral biologics discovery, vaccine market access, and gene-therapy regulatory approval.
Pharma investment is accelerating across hospitals, biosimilars, manufacturing and healthcare infrastructure, revealing changing industry growth priorities.
Gilead just raised the bar in the long-acting HIV prevention race with expanded licensing for investigational once-yearly lenacapavir.
A new MRI dye could help map tiny lung tumors and hidden metastases, offering earlier detection without radiation.
India's 'Pharmacy of the World' tag faces fresh scrutiny as a Supreme Court PIL seeks stronger action against fake drugs, counterfeit medicines, and enforcement gaps.
Pharma faces a pipeline paradox today as companies chase AI-powered R&D while trial failures, IP battles, and quality gaps widen.
Alkem’s NeuCeno brings cenobamate to Indian patients, offering a once-daily anti-seizure treatment option for adults with partial-onset seizures.
Hospital consumables could be next in line for NPPA price control as regulators examine steep markups and growing calls for structured price monitoring.
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")